Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, USA.
J Infect Dis. 2024 Jul 25;230(1):2-4. doi: 10.1093/infdis/jiae099.
Food and Drug Administration approval of the first microbiome therapies represents a true expansion the treatment paradigm for Clostridioides difficile but raises new questions about the future role of fecal microbiota transplantation. The authors outline the advances in microbiome therapeutic development that have addressed fecal microbiota transplantation's (FMT's) inherent limitations of safety and scalability. The authors also suggest that as microbiome therapeutic development continues for other indications, FMT will likely remain a necessary model of human microbiota dynamics for translational research.
食品和药物管理局批准的第一个微生物组疗法真正拓展了艰难梭菌的治疗模式，但也提出了关于粪便微生物群移植未来作用的新问题。作者概述了微生物组治疗开发方面的进展，这些进展解决了粪便微生物群移植（FMT）在安全性和可扩展性方面固有的局限性。作者还认为，随着其他适应症的微生物组治疗开发的继续，FMT 可能仍然是转化研究中人类微生物组动态的必要模型。
